FACTOR THERAPEUTICS

A Potential Game Changer in Advanced Wound Care

Dr Rosalind Wilson, CEO

Broker Meets Biotech

August 2018

Disclaimer

- The information contained in this presentation is not intended to be an offer for subscription, invitation or recommendation with respect to shares in any jurisdiction.
- No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained in this document or opinions expressed in the course of this presentation. The information contained in this presentation is subject to change without notification.
- This presentation contains forward-looking statements which can be identified by the use of words such as “may”, “should”, “will”, “expect”, “anticipate”, “believe”, “estimate”, “intend”, “scheduled” or “continue” or similar expressions. Any forward-looking statements contained in this presentation are subject to significant risks, uncertainties, assumptions, contingencies and other factors (many of which are outside the control of, and unknown to Factor Therapeutics Limited, and its officers, employees, agents or associates), which may cause the actual results or performance to be materially different from any future result so performed, expressed or implied by such forward-looking statements.
- There can be no assurance or guarantee that actual outcomes will not differ materially from these statements. Photographs of clinical subjects used in this presentation are illustrative of medical conditions associated with potential applications of VF001. Actual clinical results may vary from those shown.
- Relevant images accessed under Creative Commons.

Overview

- Rapidly approaching a **key milestone** – Phase 2 readout, VF001 in venous leg ulcers
- Successful Phase 2 is a **major catalyst**
  - Clinical proof-of-concept for VF001 as a new wound healing treatment
  - Validated platform technology – targeted growth factor delivery
- **Clear priorities** for the next 12-18 months
  - Submit dossier for EU CE Mark assessment
  - Progress towards US Phase 3 readiness
  - Progress our pipeline
  - Drive partnering discussions post-readout

Factor Therapeutics: Company Overview

Focus	Advanced wound care/dermatology research and development
Core Technology	Targeted growth factors to promote wound healing and repair
Lead Programme	VF001 for venous leg ulcer (VLU) healing – approaching Phase 2 readout (CY Q4 2018)
Commercial Potential	US$3B market for ulcer healing, CAGR ~4%
Upcoming Value Inflections	EU submission – leading to CE Mark for medical device US FDA meeting to finalise Phase 3 – towards Biologics Licence Application, BLA
De-Risked	Highly promising clinical data, validated manufacturing
Pipeline	We are a multiple-product company, covering a wide range of advanced wound care applications
IP	Excellent granted patent portfolio with commercially useful timelines

Market Overview

Share Price At 15 August 2018	$0.054
Market Cap.	$45m
Issued Shares	834,335,633
Options	36,209,320
Cash At 30 June 2018	AUD $6.4m
Symbol	FTT
Exchange	ASX



Substantial Shareholders	% Issued Capital
Allan Gray Investment Management	14.69%
Fidelity Investment Management	9.86%

Our Pipeline



2019 Focus

- VLU: Phase 3 ready
- DFU: Initiate Phase 2
- Ocular: Initiate Phase 1
- H.I.: Progress preclinical/formulation
- VF00X: Identify next pipeline molecule

1. Persistent corneal epithelial defect

VF001 – Currently in Phase 2



Normal skin
Skin surface – epithelium – forms a protective barrier
Cells are supported within a protein scaffold – the extracellular matrix (ECM)



Chronic wound
Damaged epithelium and loss of ECM
Normal healing processes become stalled



Healing with VF001
VF001 binds to the wound bed, restoring the ECM and delivers the growth factor, IGF-1
IGF-1 stimulates skin cells to attach to, move and multiply across the wound

The Home Stretch

- 136 patients completed
- 20 patients progressing towards last visit



Population Data Looks Good

- BLINDED data i.e. 1/3 placebo, 2/3 VF001, patients who have completed treatment

  ⇒ Rapid wound area reduction – 50% within 4 weeks

  ⇒ At week 12 ~70% wound area reduction and ~50% patients fully healed

- Informal benchmark vs VenUS III study

  – Similar wound type to VF00102, standard care treatment

  ⇒ At week 12 ~55% wound area reduction and ~40% of patients fully healed

- VF00102 powered to detect a statistically significant difference in wound area reduction:

Placebo + standard care (SD)	60%
VF001 + SD (low & high dose)	70-80%



Note: VF00102 is a blinded study. Data shown are a composite of 1/3 patients treated with placebo and 2/3 with VF001. The benefit of adding VF001 to standard care will be determined when the study is unblinded.

EU Approval: Medical Device Conformity Assessment



Regulatory support: MedPass International
- leading specialist EU medical device regulatory consultancy

Manufacturing and Distribution

- Our established and validated manufacturing and distribution capability is a significant “plus” for potential partners
- Commercial scale manufacturing and distribution hub in Belgium
- Clinical/small-scale commercial manufacturing in US



Partnering

- Ongoing relationships with top-tier wound care and pharma firms

- Feedback is positive
  - Highly attractive market
  - Innovative technology – “several steps on from Regranex”
  - High quality Phase 2
  - Pipeline offers added value – chronic wounds and beyond

- What we’re looking for in a partner:
  - Geographic fit – parallel focus EU and US
  - EU commercialisation capability
  - Support for Phase 3 – protocol input and funding
  - Pipeline synergies a bonus

Comparator : Regranex®

- Approved in 1997 (US)/1999 (EU) – DFU only
  - Remains the only FDA-approved *medicine* for wound healing
- Topical PDGF[1] gel, US$2-3,000 per treatment course
- Efficacy (DFU)
  - 50% vs 36% fully healed
  - Time to healing 12.1 vs 20.1 weeks
- Peak sales US$100-120m in first year of launch
  - Strong demand driven by lack of other products on market
- Poor efficacy and US black box warning (2009)
  - Significant reduction in use
  - Withdrawn from EU by manufacturer (2012)
- Current sales ~US$20M

2008	J&J wound care portfolio sold as Systagenix (PE buyer)
2011	Regranex acquired by Healthpoint Biotherapeutics
2012	Healthpoint acquired by Smith & Nephew based on successful Phase 2 result for HP802-247

1. Platelet-derived growth factor

Wound Care Deals

Buyer	Seller	Year	US$m	Details
Smith & Nephew	Rotation Medical	2017	210	Company acquisition: tissue regeneration for rotator cuff repair
Organogenesis	NuTech Medical	2017	n.d.	Tissue based incl. amniotic products for wound healing
Allergan	KCI (Acelity)	2017	2900	Acquisition of Lifecell (0.9B above 2008 price)
Integra	Derma Sciences	2017	204	Company acquisition: portfolio including amniotic product w/ reimbursement
Svenska Cellulosa Aktiebolaget ("SCA")	BSN Medical GmbH	2016	3100	Company acquisition from PE (wound care, compression therapy & orthopaedics)
Derma Sciences	BioD, LLC	2016	78	Four product families of allografts from placental tissue
Integra	TEI Biosciences/TEI Medical	2015	312	Company acquisition: PriMatrix® Dermal Repair Scaffold
Organogenesis	Shire	2014	300	Dermagraft
KCI (Acelity)	Systagenix	2013	485	Former J&J Wound Care portfolio
Integra	Covidien	2013	265	Confluent Surgical product lines incl. surgical sealants, adhesion barrier, DuraSeal™
Smith & Nephew	HealthPoint Biotherapeutics	2012	782	Company acquisition: Santyl (debriding agent) and HP802-247 (Phase 3)
Shire	Advanced BioHealing	2011	750	Dermagraft
KCI (Acelity)	LifeCell Corporation	2008	1700	Company acquisition: tissue based products incl. wound healing

In Summary

Results imminent

Rapidly approaching a key milestone and catalyst for the company

Preparing to move rapidly from readout to regulatory interactions

Intensified business development activity – building anticipation

Experienced Management Team

Dr Rosalind Wilson, CEO

Dr Wilson's career has spanned a variety of senior leadership and advisory roles, from small, innovation-led businesses, to global biopharma, including strategy and portfolio management roles at F.Hoffman-LaRoche (Roche Australia, UK and Switzerland), and Business Manager at NucleusX.

Mr Anthony Bishop, Project Director

Mr Bishop has broad experience in a wide range of drug development and management roles. He previously worked for Quintiles in Australia and Asia in business development and project management roles, as well as leading drug development projects at CSL, Chakra Biotech and MerLion Pharmaceuticals.

Dr Gary Shooter, Director of R&D

Dr Shooter is an experienced Protein Chemist with a proven track record in the GMP manufacture and characterisation of protein-based therapeutics and products. Prior to joining Factor Therapeutics, Dr Shooter was a Senior Research Fellow and Leader of the Tissue Repair and Regeneration Program at QUT.

Ms Saskia Jo, Director of Finance

Ms Jo has over 10 years' commercial experience in finance and compliance. She has been with the Company since 2011. Ms Jo's prior experience includes international sales with Shiseido Company in Tokyo followed by five years in accounting and finance functions with Burrell Stockbroking.

Mr Michael Larcom, Director of Quality

Mr Larcom is an experienced Quality Assurance (QA) professional in the pharmaceutical and medical device industries. He has key skills in pharmaceutical formulation and process development, internal and external audits (FDA, TGA and other third party audits), supplier relationship management, CAPA, validation, quality systems and start up.

Board of Directors

Dr Cherrell Hirst, Chairman

Dr Hirst has had a distinguished clinical career, in breast cancer detection and diagnosis; and extensive and respected achievements as a director of multiple commercial, government and not-for-profit companies, including a number of life sciences start-ups. She also chairs the Advisory Board of the Institute of Molecular Biosciences at UQ.

Dr Christian Behrenbruch, NED

Dr Behrenbruch has over 15 years of healthcare executive leadership experience, including roles as CEO (and executive director) at Mirada Solutions, CTI Molecular Imaging, and ImaginAb, Inc. Dr Behrenbruch is currently the CEO of Telix Pharmaceuticals Limited.

Mr Timothy Hughes, NED

Mr Timothy Hughes has over 30 years' experience in senior roles in the investment management and investment banking industries, including as Chief Investment Officer at Rothschild Australia and Catholic Super. Mr Hughes currently sits on the Investment Committee of HESTA.

Mr John Michailidis, NED

Mr. Michailidis is a seasoned pharmaceutical executive of 30 years, having held a number of C-suite positions in global companies such as Roche and as CEO of biotech and specialty companies such as AviPep and Orphan Australia. More recently John was the first Managing Director of Teva Pharma Pty Ltd, where he set up operations in Australia/New Zealand.

Dr Robert Ryan, NED

Dr. Ryan has more than 27 years of research, pharmaceutical and biotech experience spanning global development across a wide variety of regulatory and clinical activities. Dr. Ryan is currently the President and CEO of Innova Therapeutics, and prior to this position held senior management roles at Scioderm, Roche, Bristol-Myers Squibb (BMS) and Pfizer.

Ms Melanie Farris, Company Secretary

Ms Farris is an experienced governance professional and currently Chair of Synapse Australia Limited. She also holds governance roles with Telix Pharmaceuticals Limited (ASX:TLX), Invion Limited (ASX:IVX), Amplia Therapeutics Pty Ltd and Menzies Research Centre Limited.